Clinical Trial ProgressThe Phase 3 ACTION study for ONC201 is progressing, with an increasing number of study sites and patient enrollment expected to accelerate.
Financial HealthThe company's cash reserve is seen as sufficient to support its clinical programs, with management confident in funding into the fourth quarter of 2026.
Regulatory MilestonesONC201 has received Fast Track Designation and Rare Pediatric Disease Designation from the FDA, indicating regulatory support and potential for expedited development.